FDA's ISTAND Pilot Program accepts a submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury (DILI)
FDA accepts first letter of intent (LOI) into the ISTAND Pilot Program for an organ-on-a-chip techno...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- FDA Drug Approvals
- Region
- USA
- Scope
- Regulatory
- Published
- April 9, 2026
- Language
- EN
Topics
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
FDA accepts first letter of intent (LOI) into the ISTAND Pilot Program for an organ-on-a-chip techno...
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Approvals
Scope: Regulatory
Related coverage